# BioStem Technologies, Inc. (BSEM) — relisting/uplisting [completed]
Source: SEC API (secapi.ai) · situation sit_4db0051edf42c4a3bf86 · retrieved 2026-08-12T07:00:17.113Z

## Overview
BioStem Technologies, Inc. is a biomedical innovator focused on developing, manufacturing, and commercializing advanced allograft solutions derived from perinatal tissue, leveraging proprietary BioRetain®, CryoTek®, and SteriTek® processing technologies.

BioStem Technologies, Inc., a regenerative medicine company focused on perinatal tissue allograft products, announced on August 6, 2026 that The Nasdaq Stock Market LLC approved its common stock for listing on The Nasdaq Capital Market. Trading transitioned from the OTC Basic Market to Nasdaq effective August 7, 2026, under the ticker symbol "BSEM." No shareholder action was required in connection with the listing.

## Terms
- Counterparty: The Nasdaq Stock Market LLC

## Key dates
- Completed 2026-08-07

## Timeline
- 2026-08-07 · 8-K (0001193125-26-340271): 8-K - BioStem Technologies, Inc. — *BioStem Technologies, Inc. is a biomedical innovator focused on developing, manufacturing, and commercializing advanced allograft solutions derived from perinatal tissue, leveraging proprietary BioRetain®, CryoTek®, and SteriTek® processing technologies.* BioStem Technologies, Inc., a regenerative medicine company focused on perinatal tissue allograft products, announced on August 6, 2026 that The Nasdaq Stock Market LLC approved its common stock for listing on The Nasdaq Capital Market. Trading transitioned from the OTC Basic Market to Nasdaq effective August 7, 2026, under the ticker symbol "BSEM." No shareholder action was required in connection with the listing.
  https://www.sec.gov/Archives/edgar/data/1658678/0001193125-26-340271.txt

## Citations
- 0001193125-26-340271 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526340271